Cargando…
Prevalence, Demographics, and Treatment Characteristics of Visual Impairment due to Diabetic Macular Edema in a Representative Canadian Cohort
Diabetic macular edema (DME) is the leading cause of blindness in the diabetic population. However, there is limited understanding of the epidemiology of DME with visual impairment (VI) and treatment in patients with diabetes in Canada. This observational, retrospective study used records from the S...
Autores principales: | Petrella, Robert J., Blouin, Julie, Davies, Brian, Barbeau, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529901/ https://www.ncbi.nlm.nih.gov/pubmed/23304447 http://dx.doi.org/10.1155/2012/159167 |
Ejemplares similares
-
Incidence and Characteristics of Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion in a Representative Canadian Cohort
por: Petrella, Robert J., et al.
Publicado: (2012) -
Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)
por: Gonder, John R., et al.
Publicado: (2014) -
Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
por: Bandello, Francesco, et al.
Publicado: (2011) -
Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)
por: Menchini, Ugo, et al.
Publicado: (2015) -
Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
por: Kourlaba, Georgia, et al.
Publicado: (2016)